| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
CMD178 TFA targets STAT5, a transcription factor involved in IL-2 signaling and Treg cell development. By inhibiting STAT5, it reduces the expression of Foxp3, the master regulator of Treg cell differentiation, induced by IL-2/sIL-2Rα signaling.
|
|---|---|
| ln Vitro |
CMD178 TFA (100 μM) reduces Foxp3 expression in T cells and lowers IL-2-induced STAT5 phosphorylation[1]. IL2/sIL-2Rα signaling-induced Treg cell growth is inhibited by CMD178 TFA (100 μM)[1].
In vitro, CMD178 TFA consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/sIL-2Rα signaling. It inhibits Treg cell development. The peptide is validated for in vitro functional assays. |
| ln Vivo |
In vivo, CMD178 TFA is validated for use in murine models of immune modulation. By inhibiting STAT5 and reducing Foxp3 expression, it may modulate Treg cell development and immune responses in vivo.
|
| Enzyme Assay |
Non-cellular binding assays for CMD178 TFA would typically involve measuring its binding affinity to STAT5. These assays can be performed using surface plasmon resonance (SPR) or other biophysical techniques with purified STAT5 protein.
|
| Cell Assay |
In vitro cellular assays for CMD178 TFA are performed using T cells or other immune cells. Cells are treated with the peptide, and the expression of Foxp3 and STAT5 is measured by qRT-PCR or Western blotting. The compound's effect on Treg cell development is assessed by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for CMD178 TFA are conducted in murine models of immune modulation. The compound is administered via appropriate routes, and endpoints include assessment of Treg cell development, immune response modulation, and disease progression in autoimmune models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for CMD178 TFA are not detailed in available sources. The compound has a molecular weight of 964.05 kDa and a purity of 99.83%. Its molecular formula is C48H60F3N9O9. It is supplied as a synthetic peptide (free form or TFA salt, ≥98% purity).
|
| Toxicity/Toxicokinetics |
Toxicological data for CMD178 TFA are not provided in available sources. As a research peptide, its safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
CMD178 TFA is a lead peptide that reduces the expression of Foxp3 and STAT5 induced by IL-2/sIL-2Rα signaling and inhibits Treg cell development. It is validated for in vitro functional assays and in vivo murine models of immune modulation. No clinical trial or regulatory approval information is available.
|
| Molecular Formula |
C9H8F5KO3Y
|
|---|---|
| Molecular Weight |
964.05
|
| Related CAS # |
CMD178
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~2.5 mg/mL (~2.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0373 mL | 5.1865 mL | 10.3729 mL | |
| 5 mM | 0.2075 mL | 1.0373 mL | 2.0746 mL | |
| 10 mM | 0.1037 mL | 0.5186 mL | 1.0373 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
